Cumberland Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CUMBERLAND, and when can generic versions of CUMBERLAND drugs launch?
CUMBERLAND has eight approved drugs.
There are seventeen US patents protecting CUMBERLAND drugs.
There are one hundred and thirty-one patent family members on CUMBERLAND drugs in thirty-eight countries and fourteen supplementary protection certificates in twelve countries.
Drugs and US Patents for Cumberland
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-003 | Jan 25, 2019 | RX | Yes | Yes | 11,806,400 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cumberland | VAPRISOL | conivaptan hydrochloride | INJECTABLE;INTRAVENOUS | 021697-001 | Dec 29, 2005 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-003 | Jan 25, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Cumberland Pharms | LACTULOSE | lactulose | FOR SOLUTION;ORAL | 074712-001 | Dec 10, 1997 | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Cumberland
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-002 | Jun 11, 2009 | 6,727,286 | ⤷ Try a Trial |
Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 7,208,471 | ⤷ Try a Trial |
Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 6,635,618 | ⤷ Try a Trial |
Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | 8,101,575 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CUMBERLAND drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Transdermal System | 3.1 mg/24 hrs | ➤ Subscribe | 2015-10-09 |
➤ Subscribe | Injection | 200 mg/mL, 30 mL vials | ➤ Subscribe | 2012-04-04 |
International Patents for Cumberland Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Hungary | E026769 | ⤷ Try a Trial |
Canada | 2726967 | ⤷ Try a Trial |
Poland | 379027 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2010105129 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cumberland Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1292612 | PA2012002 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902 |
1292612 | SPC/GB11/056 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTERED: UK EU/1/11/705/001 20110906; UK EU/1/11/705/002 20110906 |
1292612 | CA 2011 00033 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID |
1292612 | 2011/037 | Ireland | ⤷ Try a Trial | PRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.